Anika Therapeutics ANIK Inventory write-downs
Inventory write-downs at other companies
Other financials
Where this comes from
Reported directly by Anika Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InventoryWriteDown.
The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Anika Therapeutics's inventory write-downs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Anika Therapeutics's inventory write-downs?
- Anika Therapeutics (ANIK) reported inventory write-downs of $1.03M in Q1 2026.
- How has Anika Therapeutics's inventory write-downs changed year-over-year?
- Anika Therapeutics's inventory write-downs increased by 24.0% year-over-year, from $832K to $1.03M.
- What is the long-term trend for Anika Therapeutics's inventory write-downs?
- Over 4 years (2021 to 2025), Anika Therapeutics's inventory write-downs has grown at a 4.4% compound annual growth rate (CAGR), from $4.9M to $5.82M.
- What does inventory write-downs mean?
- This represents the reduction in the value of inventory when its cost exceeds its net realizable value due to obsolescence, damage, or market price declines. It is a critical indicator of inventory management efficiency and product demand alignment. High write-downs suggest potential issues with supply chain forecasting or product lifecycle management.